Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: A phase II trial

被引:169
作者
Delanian, S
Depondt, J
Lefaix, JL
机构
[1] Serv Oncol Radiotherapie, F-75010 Paris, France
[2] Hop Bichat Claude Bernard, Chirurg Cerv Faciale, APHP, F-75877 Paris, France
[3] CEN, FAR, DSV, DRR, F-92265 Fontenay Aux Roses, France
来源
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2005年 / 27卷 / 02期
关键词
osteoradionecrosis; radiotherapy; pentoxifylline; tocopherol; clodronate;
D O I
10.1002/hed.20121
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background. Osteoradionecrosis (ORN) is a non-healing wound of the bone that is difficult to manage. Is a treatment combining pentoxifylline (PTX) and tocopherol (vitamin E) boosted by clodronate effective in reversing this filbronecrotic process? Methods. Eighteen consecutive patients previously irradiated for head and neck cancer had exteriorized mandible ORN. Length of exposed bone (L) was 13.4 +/- 8 mm, and the mean subjective objective medical management and analytic evaluation of injury (SOMA) score was 12.6 +/- 4.9. Between June 1995 and January 2002, all 18 were given a daily oral combination of 800 mg of PTX and 1000 IU of vitamin E for 6 to 24 months, In addition, the last eight patients who were the worst cases were given 1600 mg/day clodronate 5 days a week. Results. The treatment was well tolerated. All patients improved at 6 months, with 84% mean L and 67% mean SOMA score reductions. Sixteen (89%) of 18 patients achieved complete recovery, 14 in 5 +/- 2.6 months. The remaining two patients exhibited a 75% response at 6 months. Conclusion. PTX-vitamin E boosted by clodronate is an effective treatment of mandibular ORN that induces mucosal and bone healing in a median period of 6 months. (C) 2005 Wiley Periodicals, Inc. Head Neck 27: 114-123, 2005
引用
收藏
页码:114 / 123
页数:10
相关论文
共 47 条
[1]  
AITASALO K, 1986, PLAST RECONSTR SURG, V77, P256, DOI 10.1097/00006534-198602000-00015
[2]  
ANNANE D, 2004, IN PRESS J CLIN ONCO, V22
[3]   Extended safety profile of oral clodronate after long-term use in primary breast cancer patients [J].
Atula, S ;
Powles, T ;
Paterson, A ;
McCloskey, E ;
Nevalainen, J ;
Kanis, J .
DRUG SAFETY, 2003, 26 (09) :661-671
[4]  
BALOGH JM, 1989, J OTOLARYNGOL, V18, P245
[5]   OSTEONECROSIS IN PATIENTS TREATED WITH DEFINITIVE RADIOTHERAPY FOR SQUAMOUS-CELL CARCINOMAS OF ORAL CAVITY AND NASOPHARYNX AND OROPHARYNX [J].
BEDWINEK, JM ;
SHUKOVSKY, LJ ;
FLETCHER, GH ;
DALEY, TE .
RADIOLOGY, 1976, 119 (03) :665-667
[6]   Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death -: Evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt [J].
Bezzi, M ;
Hasmim, M ;
Bieler, G ;
Dormond, O ;
Rüegg, C .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (44) :43603-43614
[7]   OSTEORADIONECROSIS OF THE MANDIBLE - PATHOGENESIS [J].
BRAS, J ;
DEJONGE, HKT ;
VANMERKESTEYN, JPR .
AMERICAN JOURNAL OF OTOLARYNGOLOGY, 1990, 11 (04) :244-250
[8]   BISPHOSPHONATES DIRECTLY INHIBIT THE BONE-RESORPTION ACTIVITY OF ISOLATED AVIAN OSTEOCLASTS INVITRO [J].
CARANO, A ;
TEITELBAUM, SL ;
KONSEK, JD ;
SCHLESINGER, PH ;
BLAIR, HC .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (02) :456-461
[9]  
COSTANTINO PD, 1995, OTOLARYNG CLIN N AM, V28, P1021
[10]  
Dambrain R., 1993, Revue de Stomatologie et de Chirurgie Maxillo-Faciale, V94, P140